Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

The market for Bavencio (avelumab), the checkpoint inhibitor co-developed by Pfizer (NYSE: PFE) and Merck KGaA (MRK: DE), ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...